The capacity of adoptive T cell therapy to eradicate a large established tumor burden has been demonstrated with the re-infusion of tumor-infiltrating lymphocytes specific to melanoma,64 as well as CAR-based treatment for CD19+ B-cell malignancies.65 The gene discussed is CD19; the disease is neoplasm.